Contact Kate

Speaking Engagements

  

Design, Manufacture & Deliver Safer, More Efficacious, Globally Accessible Treatments for Solid Tumors, Leveraging γδT Mechanisms As newly published data show the first Gamma Delta T cell therapy's clinical efficacy in patients, the race to market for the first allogeneic and solid tumor-targeting γδT has begun.

26-28 July 2022
  

Turbocharge the Development of Best-in-Class Antibody & Cell-Based Approaches of Innate Immune Therapies, to Launch Safe, Globally Scalable & Efficacious Therapies from Europe The momentum of innate immune cell R&D is growing exponentially to harness innate immune responses in oncology, realise scaled allogeneic manufacturing, and drive commercial

18-20 October 2022
  

Welcome to the 2nd iPSC-Derived Cell Therapies Summit Showcasing Discovery, Translation, CMC and Regulatory Advances at the Flagship iPSC Summit Continued investment into the iPSC space is accelerating development of both autologous and off-the-shelf therapies for a broad range of indications.

06-07 December 2022
  

Welcome to the 5th Annual Cell Engager Summit! Tecytinib’s approval last year has strongly fuelled the mentality that this is the year of cell engager! Bispecifics have led the way and liquid tumors have been hit hard. Now Immunocore and others are starting to take the fight to solid tumors. The 5th Annual Cell Engager Summit returns this year de

25-27 April 2023
  

CHI’s Cell Therapy Manufacturing conference examines the practical challenges in manufacturing autologous and allogenic cell therapies at scale, with dedicated sessions on cell processing, scalability, next-generation production technologies, automation, closed systems, artificial intelligence, supply chain, and facility design. The meeting takes e

16-17 August 2023